Health Trials

Evaluation of Inflammatory Markers in ph Negative Myeloproliferative Neoplasms: Impact on Outcome and Response to Therapy. Multicenter Retro-prospective Observational Study. The INFLA-ME (INFLAmmation in Myeloproliferative Disease) Study.

ConditionsMyeloproliferative DiseaseInflammatory Markers
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-99
SponsorUniversity of Milano Bicocca

About this trial

This study aims to observe inflammatory biomarkers and their trend over the history of the disease in patients suffering from MPN Ph negative; it also wants to identify any correlations between the aforementioned biomarkers and disease outcomes, considering first of all the occurrence of thrombo-haemorrhagic events and the evolution in the accelerated / blast phase of the disease, shedding light on new tools that can potentially guarantee a prompt and better risk stratification

Eligibility criteria

Qualifiers

Age ≥ 18 years at the time of diagnosis of MPN Ph negative

Diagnosis of PV, ET, PMF or post PV and post ET MF, according to current WHO or IWG-MRT criteria (diagnosis since 2000)

Obtaining informed consent

Disqualifiers

Life expectancy of less than 6 months

Accelerated phase myelofibrosis or MPN with signs of leukemic evolution

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

No trial groups listed

Locations

11
Azienda Ospedaliera Universitaria Consorziale Policlinico Bari Italy
Policlinico Sant'Orsola Malpighi Bologna Italy
ASST Spedali Civili di Brescia Brescia Italy
Policlinico Vittorio Emanuele Catania Italy

Sponsors and collaborators

University of Milano Bicocca

Lead sponsor

Source ClinicalTrials.gov